Human ErbB3/Her3 Antibody | R&D Systems MAB3481-100 product information

product summary

company name :

R&D Systems

product type :

antibody

product name :

Human ErbB3/Her3 Antibody

catalog :

MAB3481-100

quantity :

100 ug (also 25 ug, 500 ug)

price :

489 USD

clonality :

monoclonal

host :

mouse

conjugate :

nonconjugated

clone name :

66223

reactivity :

human

application :

western blot, ELISA, neutralization, immunoprecipitation, flow cytometry

more info or order :

R&D Systems product webpage

citations: 21

Reference
Lyu N, Pedersen B, Shklovskaya E, Rizos H, Molloy M, Wang Y. SERS characterization of colorectal cancer cell surface markers upon anti-EGFR treatment. Exploration (Beijing). 2022;2:20210176 pubmed publisher
Moody T, Ramos Álvarez I, Jensen R. Adding of neurotensin to non-small cell lung cancer cells increases tyrosine phosphorylation of HER3. Peptides. 2022;156:170858 pubmed publisher
El Hallal R, Lyu N, Wang Y. Effect of Cetuximab-Conjugated Gold Nanoparticles on the Cytotoxicity and Phenotypic Evolution of Colorectal Cancer Cells. Molecules. 2021;26: pubmed publisher
Khan T, Seddon A, Dalgleish A, Khelwatty S, Ioannou N, Mudan S, et al. Synergistic activity of agents targeting growth factor receptors, CDKs and downstream signaling molecules in a panel of pancreatic cancer cell lines and the identification of antagonistic combinations: Implications for future clinical trials in pancr. Oncol Rep. 2020;44:2581-2594 pubmed publisher
Moody T, Lee L, Jensen R. The G Protein-Coupled Receptor PAC1 Regulates Transactivation of the Receptor Tyrosine Kinase HER3. J Mol Neurosci. 2021;71:1589-1597 pubmed publisher
Wang J, Wuethrich A, Sina A, Lane R, Lin L, Wang Y, et al. Tracking extracellular vesicle phenotypic changes enables treatment monitoring in melanoma. Sci Adv. 2020;6:eaax3223 pubmed publisher
Lee L, Ramos Álvarez I, Moody T, Mantey S, Jensen R. Neuropeptide bombesin receptor activation stimulates growth of lung cancer cells through HER3 with a MAPK-dependent mechanism. Biochim Biophys Acta Mol Cell Res. 2020;1867:118625 pubmed publisher
Wang J, Anderson W, Li J, Lin L, Wang Y, Trau M. A high-resolution study of in situ surface-enhanced Raman scattering nanotag behavior in biological systems. J Colloid Interface Sci. 2019;537:536-546 pubmed publisher
Memon A, Gilliver S, Borre M, Sundquist J, Sundquist K, Nexo E, et al. Soluble HER3 predicts survival in bladder cancer patients. Oncol Lett. 2018;15:1783-1788 pubmed publisher
Pool M, Kol A, de Jong S, de Vries E, Lub de Hooge M, Terwisscha van Scheltinga A. 89Zr-mAb3481 PET for HER3 tumor status assessment during lapatinib treatment. MAbs. 2017;9:1370-1378 pubmed publisher
Le Clorennec C, BAZIN H, Dubreuil O, Larbouret C, Ogier C, Lazrek Y, et al. Neuregulin 1 Allosterically Enhances the Antitumor Effects of the Noncompeting Anti-HER3 Antibody 9F7-F11 by Increasing Its Binding to HER3. Mol Cancer Ther. 2017;16:1312-1323 pubmed publisher
Puvanenthiran S, Essapen S, Seddon A, Modjtahedi H. Impact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of small molecule tyrosine kinase inhibitors and cytotoxic drugs. Int J Oncol. 2016;49:1825-1838 pubmed publisher
Hatch A, Sibley A, Starr M, Brady J, Jiang C, Jia J, et al. Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance). Cancer Med. 2016;5:2249-60 pubmed publisher
Ioannou N, Seddon A, Dalgleish A, Mackintosh D, Solca F, Modjtahedi H. Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER-inhibitors is accompanied by increased sensitivity to STAT3 inhibition. Int J Oncol. 2016;48:908-18 pubmed publisher
Fock V, Plessl K, Draxler P, Otti G, Fiala C, KnÃ¶fler M, et al. Neuregulin-1-mediated ErbB2-ErbB3 signalling protects human trophoblasts against apoptosis to preserve differentiation. J Cell Sci. 2015;128:4306-16 pubmed publisher
Liu Z, Leng E, Gunasekaran K, Pentony M, Shen M, Howard M, et al. A novel antibody engineering strategy for making monovalent bispecific heterodimeric IgG antibodies by electrostatic steering mechanism. J Biol Chem. 2015;290:7535-62 pubmed publisher
Ioannou N, Dalgleish A, Seddon A, Mackintosh D, Guertler U, Solca F, et al. Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells. Br J Cancer. 2011;105:1554-62 pubmed publisher
Khelwatty S, Essapen S, Seddon A, Modjtahedi H. Growth response of human colorectal tumour cell lines to treatment with afatinib (BIBW2992), an irreversible erbB family blocker, and its association with expression of HER family members. Int J Oncol. 2011;39:483-91 pubmed publisher
Khan I, Zhao J, Ghosh P, Ziman M, Sweeney C, Kung H, et al. Microbead arrays for the analysis of ErbB receptor tyrosine kinase activation and dimerization in breast cancer cells. Assay Drug Dev Technol. 2010;8:27-36 pubmed publisher
Lin S, Lee Y, Choueiri M, Wen S, Mathew P, Ye X, et al. Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer. Clin Cancer Res. 2008;14:3729-36 pubmed publisher
Lin S, Cheng C, Lee Y, Ye X, Tsai W, Kim J, et al. A 45-kDa ErbB3 secreted by prostate cancer cells promotes bone formation. Oncogene. 2008;27:5195-203 pubmed publisher

product information

brand :

R&D Systems

master code :

MAB3481

SKU :

MAB3481-100

product name :

Human ErbB3/Her3 Antibody

unit size :

100 ug (also 25 ug, 500 ug)

seo description :

The Human ErbB3/Her3 Antibody from R&D Systems is a mouse monoclonal antibody to ErbB3/Her3. This antibody reacts with human. The Human ErbB3/Her3 Antibody has been validated for the following applications: Flow Cytometry,Dynamic Light Scattering,ELISA Development,ELISA Development (Capture),Luminex Development,Immunoprecipitation,Western Blot,Neutralization,ELISA Capture (Matched Antibody Pair),CyTOF-ready.

target :

ErbB3/Her3

category :

Primary Antibodies

buffer :

Lyophilized from a 0.2 ╡m filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 ╡m filtered solution in PBS.

clonality :

Monoclonal

clone :

66223

conjugate :

Unconjugated

dilution :

Flow Cytometry 2.5 ug/10^6 cells, Neutralization 0.0075-0.03 ug/mL, CyTOF-ready, ELISA Capture (Matched Antibody Pair) 2-8 ug/mL

host :

Mouse

immunogen :

Mouse myeloma cell line NS0-derived recombinant human ErbB3/Her3, Ser20-Thr643, Accession # P21860

isotype :

IgG1

purity :

Protein A or G purified from hybridoma culture supernatant

species :

Human

specificity :

Detects human ErbB3/Her3 in ELISAs. Does not cross-react with recombinant EGF R.

gene symbol :

ERBB3

endotoxin note :

<0.10 EU per 1 ╡g of the antibody by the LAL method.

top caption :

Cell Proliferation Induced by NRG1-ss1/HRG1-ss1 and Neutralization by Human ErbB3/Her3 Antibody.

accessionNumbers :

P21860

applications :

ELISA Capture (Matched Antibody Pair),CyTOF-ready,Dynamic Light Scattering,ELISA Development,ELISA Development (Capture),Luminex Development,Flow Cytometry,Immunoprecipitation,Western Blot,Neutralization

USD :

489 USD

alt names :

c-erbB3, EC 2.7.10, EC 2.7.10.1, ErbB-3, erbB3-S, HER3, HER3c-erbB-3, LCCS2, lethal congenital contracture syndrome 2, MDA-BF-1, MGC88033, p180-ErbB3, p45-sErbB3, p85-sErbB3, Proto-oncogene-like protein c-ErbB-3, receptor tyrosine-protein kinase erbB-3, Tyrosine kinase-type cell surface receptor HER3, v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian)

storage :

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 ░C as supplied. 1 month, 2 to 8 ░C under sterile conditions after reconstitution. 6 months, -20 to -70 ░C under sterile conditions after reconstitution.

more info or order :

R&D Systems product webpage